Denali Therapeutics Inc (DNLI) stock is up 192.42% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives DNLI stock a score of 66 out of a possible 100.
That rank is mainly influenced by a short-term technical score of 100. DNLI's rank also includes a long-term technical score of 96. The fundamental score for DNLI is 3. In addition to the average rating from Wall Street analysts, DNLI stock has a mean target price of 37.5. This means analysts expect the stock to fall 18.27% over the next 12 months.
What's Happening with DNLI Stock Today
Denali Therapeutics Inc (DNLI) stock has gained 9.03% while the S&P 500 has fallen -0.3% as of 4:00 PM on Tuesday, Oct 27. DNLI is up $3.80 from the previous closing price of $42.08 on volume of 478,607 shares. Over the past year the S&P 500 has gained 11.56% while DNLI is up 192.42%. DNLI lost -$2.15 per share in the over the last 12 months.
Click Here to get the full Stock Score Report on Denali Therapeutics Inc (DNLI) Stock.